FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2862307131> ?p ?o ?g. }

• W2862307131 abstract "The management of proliferative lupus nephritis (LN) comprises timely and coordinated immunosuppressive therapy. This study aimed to evaluate and compare the effectiveness and safety profile of low dose mycophenolate mofetil (MMF) and cyclophosphamide (CYC) in induction therapy of LN in Nepalese population. We conducted a prospective, open-label, randomized trial over a period of one and half years. Forty-nine patients with class III to V lupus nephritis were enrolled, out of which 42 patients (21 in each group) could complete the study. CYC was given intravenously as a monthly pulse and MMF was administered orally in the tablet form in the maximum daily dose of 1.5 g in two divided doses. The mean age of the patients was 25.43 ± 10.17 years with female to male ratio of 7.3:1. Mean baseline serum creatinine was 1.58 ± 1.38 mg/dL and eGFR was 62.38 ± 26.76 ml/min/1.73m2. Mean 24-h urinary protein was 4.35 ± 3.71 g per 1.73 m2 body surface area. At 6 months, serum creatinine (mg/dL) decreased from 1.73 to 0.96 in CYC and from 1.24 to 0.91 in the MMF group with improvement in eGFR (ml/min/1.73 m2) from 60.33 to 88.52 in CYC and from 64.42 to 89.09 in MMF group. Twenty-four-hour urinary protein (gm/1.73m2) reduced from 4.47 to 0.94 in CYC and from 4.5 to 0.62 in the MMF group. Primary end point was achieved in higher percentage of patients with MMF than CYC (28.6% vs. 19%) while equal proportion of patients (67% in each group) achieved secondary end point in both groups. Number of non-responders was higher in CYC group than in the MMF group (14.3% vs. 4.8%). There was no difference in the rate of achievement of secondary end point in both CYC and MMF groups (3.16 vs. 3.05 months). The occurrence of adverse events was higher in the CYC than in MMF group (56 vs. 15 events). Present study has concluded that MMF, used in relatively lower dose, is equally effective in inducing remission with reduction of proteinuria and improvement of kidney function with lesser adverse events than CYC in the induction therapy of proliferative lupus nephritis. Retrospectively registered to ClinicalTrials.gov PRS. NCT03200002 (Registered date: June 28, 2017)." @default.
• W2862307131 created "2018-07-19" @default.
• W2862307131 creator A5028317571 @default.
• W2862307131 creator A5039075349 @default.
• W2862307131 creator A5074830394 @default.
• W2862307131 creator A5076801513 @default.
• W2862307131 creator A5087945447 @default.
• W2862307131 date "2018-07-11" @default.
• W2862307131 modified "2023-10-07" @default.
• W2862307131 title "Low dose mycophenolate mofetil versus cyclophosphamide in the induction therapy of lupus nephritis in Nepalese population: a randomized control trial" @default.
• W2862307131 cites W1591852395 @default.
• W2862307131 cites W1866542120 @default.
• W2862307131 cites W1966639889 @default.
• W2862307131 cites W1971058219 @default.
• W2862307131 cites W2000054950 @default.
• W2862307131 cites W2024442997 @default.
• W2862307131 cites W2031192725 @default.
• W2862307131 cites W2031603672 @default.
• W2862307131 cites W2033562956 @default.
• W2862307131 cites W2068121948 @default.
• W2862307131 cites W2070527591 @default.
• W2862307131 cites W2073742622 @default.
• W2862307131 cites W2090256056 @default.
• W2862307131 cites W2096194879 @default.
• W2862307131 cites W2111940985 @default.
• W2862307131 cites W2122338150 @default.
• W2862307131 cites W2123602540 @default.
• W2862307131 cites W2126132958 @default.
• W2862307131 cites W2144774241 @default.
• W2862307131 cites W2157460346 @default.
• W2862307131 cites W2159860161 @default.
• W2862307131 cites W2160388191 @default.
• W2862307131 cites W2171121999 @default.
• W2862307131 cites W2195635340 @default.
• W2862307131 cites W2325870812 @default.
• W2862307131 cites W2414784657 @default.
• W2862307131 cites W3156996711 @default.
• W2862307131 doi "https://doi.org/10.1186/s12882-018-0973-7" @default.
• W2862307131 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6042432" @default.
• W2862307131 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29996800" @default.
• W2862307131 hasPublicationYear "2018" @default.
• W2862307131 type Work @default.
• W2862307131 sameAs 2862307131 @default.
• W2862307131 citedByCount "20" @default.
• W2862307131 countsByYear W28623071312019 @default.
• W2862307131 countsByYear W28623071312020 @default.
• W2862307131 countsByYear W28623071312021 @default.
• W2862307131 countsByYear W28623071312022 @default.
• W2862307131 countsByYear W28623071312023 @default.
• W2862307131 crossrefType "journal-article" @default.
• W2862307131 hasAuthorship W2862307131A5028317571 @default.
• W2862307131 hasAuthorship W2862307131A5039075349 @default.
• W2862307131 hasAuthorship W2862307131A5074830394 @default.
• W2862307131 hasAuthorship W2862307131A5076801513 @default.
• W2862307131 hasAuthorship W2862307131A5087945447 @default.
• W2862307131 hasBestOaLocation W28623071311 @default.
• W2862307131 hasConcept C126322002 @default.
• W2862307131 hasConcept C126894567 @default.
• W2862307131 hasConcept C168563851 @default.
• W2862307131 hasConcept C2776694085 @default.
• W2862307131 hasConcept C2776755627 @default.
• W2862307131 hasConcept C2779134260 @default.
• W2862307131 hasConcept C2779912601 @default.
• W2862307131 hasConcept C2780306776 @default.
• W2862307131 hasConcept C2908647359 @default.
• W2862307131 hasConcept C2909935303 @default.
• W2862307131 hasConcept C2911091166 @default.
• W2862307131 hasConcept C54847362 @default.
• W2862307131 hasConcept C71924100 @default.
• W2862307131 hasConcept C90924648 @default.
• W2862307131 hasConcept C99454951 @default.
• W2862307131 hasConceptScore W2862307131C126322002 @default.
• W2862307131 hasConceptScore W2862307131C126894567 @default.
• W2862307131 hasConceptScore W2862307131C168563851 @default.
• W2862307131 hasConceptScore W2862307131C2776694085 @default.
• W2862307131 hasConceptScore W2862307131C2776755627 @default.
• W2862307131 hasConceptScore W2862307131C2779134260 @default.
• W2862307131 hasConceptScore W2862307131C2779912601 @default.
• W2862307131 hasConceptScore W2862307131C2780306776 @default.
• W2862307131 hasConceptScore W2862307131C2908647359 @default.
• W2862307131 hasConceptScore W2862307131C2909935303 @default.
• W2862307131 hasConceptScore W2862307131C2911091166 @default.
• W2862307131 hasConceptScore W2862307131C54847362 @default.
• W2862307131 hasConceptScore W2862307131C71924100 @default.
• W2862307131 hasConceptScore W2862307131C90924648 @default.
• W2862307131 hasConceptScore W2862307131C99454951 @default.
• W2862307131 hasIssue "1" @default.
• W2862307131 hasLocation W28623071311 @default.
• W2862307131 hasLocation W28623071312 @default.
• W2862307131 hasLocation W28623071313 @default.
• W2862307131 hasLocation W28623071314 @default.
• W2862307131 hasLocation W28623071315 @default.
• W2862307131 hasOpenAccess W2862307131 @default.
• W2862307131 hasPrimaryLocation W28623071311 @default.
• W2862307131 hasRelatedWork W1966401754 @default.
• W2862307131 hasRelatedWork W2055678110 @default.
• W2862307131 hasRelatedWork W2088391963 @default.
• W2862307131 hasRelatedWork W2320042542 @default.
• W2862307131 hasRelatedWork W2345884250 @default.
• W2862307131 hasRelatedWork W2587984886 @default.

• next